Investigators reported that enfortumab vedotin-ejfv (Padcev; Astella Pharma Inc, Seagen Inc) in combination with pembrolizumab (Keytruda; Merck & Co Inc) met the dual primary endpoints of overall survival and progression-free survival in patients with previously untreated locally advanced or metastatic urothelial cancer.
Munster Technological University Kerry says Astellas’ plans will further enhance Kerry’s reputation as a STEM centre of excellence.Astella Pharma Inc. today ann.